<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240725062542N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-11-28</date_registration>
      <primary_sponsor>Qazvin University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Dignity Therapy on the Demoralization in Patients Undergoing Chemotherapy in Qazvin City, 2024</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Dignity Therapy on the Demoralization in Patients Undergoing Chemotherapy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-12-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>84</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/79752</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Other, Purpose: Education/Guidance, Randomization description: 1. Participants will be selected based on inclusion criteria and availability through a convenience sampling method.
2. After selection, they will be assigned to either group using a simple randomization with balanced blocks.
3. Given the study's two-group nature, a balanced block randomization with a block size of 4 will be employed for the randomization.
4. To determine the randomization order by a block of 4, an online tool for producing random allocation lists (https://www.sealedenvelope.com/simple-randomiser/v1/lists) will be used.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Cancer, Chemotherapy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group: Dignity therapy is a brief individual therapy in which the therapist asks a series of open-ended questions to the patient within a 30 to 60-minute session, encouraging them to talk about their life and significant events. The patient's speech is recorded, rewritten, and edited. After a few days, it is returned to the patient to allow the creation of necessary changes before the final version is prepared. The final version is kept as a booklet as a memento for the patient's family and loved ones. Intervention 2: Control Group: In the control group, questionnaires are completed initially, immediately after the intervention, and 3 months post-intervention. At the end, a booklet containing educational points on the disease and points that should be observed during the disease is given to the patient.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link>https://www.sciencedirect.com/science/article/abs/pii/S1462388925001589</results_url_link>
      <results_summary>Abstract
Purpose
 Demoralization is a common psychological distress experienced by cancer patients undergoing chemotherapy. This study aimed to evaluate the effectiveness of nurse-led dignity therapy in reducing demoralization syndrome among this patient population.
Methods
 A randomized controlled trial was conducted with 84 patients undergoing chemotherapy, who were allocated to either an intervention group (n = 42) receiving three sessions of dignity therapy by a trained oncology nurse, or a control group (n = 42) receiving standard care. Assessments were performed at baseline, one month, and three months post-intervention using a demographic questionnaire and the Demoralization Scale (DS). Data were analyzed using repeated-measures multivariate analysis of variance (MANOVA-RM) to examine changes in demoralization over time and between groups.
Results
 The intervention group showed a significant reduction in demoralization symptoms compared to controls (P &lt; 0.001, standardized mean difference = –1.65). The group-by-time interaction was significant (P = 0.006), indicating that the effects were maintained at follow-up.
Conclusions
 Nurse-led dignity therapy is an effective psychotherapeutic intervention to alleviate demoralization syndrome in patients undergoing chemotherapy. Its integration into oncology nursing practice may enhance psychological outcomes and overall patient care.
Keywords: Cancer, Chemotherapy, Dignity Therapy, Demoralization, Nurse-led Intervention</results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data collected will potentially be shareable after the participants have been de-identified.

When:
The data will be available 6 months after the study results have been published.

To whom:
The data will only be accessible to researchers affiliated with academic and research institutions.

Conditions:
The results of this study may be used by researchers for future studies, provided that they obtain permission from the project coordinators.

Where to obtain:
Executors of the plan: Sima Kazemi (nurse.simakazemi@gmail.com)
Mohammad Ali Soleimani (soleimany.msn@gmail.com)

How to obtain:
Please contact us via email for further communication.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sima Kazemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nursing and Midwifery, Qazvin University of Medical Sciences, Bahonar Blvd, Qazvin, Iran</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>59811-34197</zip>
        <telephone>+98 28 3333 6001</telephone>
        <email>nurse.simakazemi@gmail.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Ali Soleimani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nursing and Midwifery, Qazvin University of Medical Sciences, Bahonar Blvd, Qazvin, Iran</address>
        <city>Qazvin</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>59811-34197</zip>
        <telephone>+98 28 3333 6001</telephone>
        <email>soleimany.msn@gmail.com</email>
        <affiliation>Qazvin University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Willingness to participate in the research and complete the consent form 2. Full consciousness and the ability to communicate 3. People over 18 years old 4. Being literate in reading and writing in the Persian language 5. Starting chemotherapy at least 6 months ago 6. Access to a phone or mobile for follow-up</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Diagnosis of a psychiatric disorder and use of psychotropic drugs (as diagnosed by a physician) 2. Experience of spiritual crises in the last 6 months (self-report) 3. Use of alcohol and drugs (self-report)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z51.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Maintenance chemotherapy NOS</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Behavior</i_code>
      <i_code>Behavior</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group: Dignity therapy is a brief individual therapy in which the therapist asks a series of open-ended questions to the patient within a 30 to 60-minute session, encouraging them to talk about their life and significant events. The patient's speech is recorded, rewritten, and edited. After a few days, it is returned to the patient to allow the creation of necessary changes before the final version is prepared. The final version is kept as a booklet as a memento for the patient's family and loved ones.</i_keyword>
      <i_keyword>Control Group: In the control group, questionnaires are completed initially, immediately after the intervention, and 3 months post-intervention. At the end, a booklet containing educational points on the disease and points that should be observed during the disease is given to the patient.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>This is a score that each participant will receive based on the 24-item Distress Thermometer scale developed by Kissane (2004). Timepoint: The Demoralization Syndrome questionnaire will be administered at three different time points: before the intervention, immediately after the intervention, and three months post-intervention for follow-up. Method of measurement: The Demoralization Syndrome (DS) is a tool designed by Kissane and colleagues (2004) to assess Demoralization Syndrome in cancer patients.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Qazvin University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-10-22</approval_date>
        <contact_name>Ethics Committee of Qazvin University of Medical Sciences</contact_name>
        <contact_address>Faculty of Nursing and Midwifery, Qazvin University of Medical Sciences, Bahonar Blvd, Qazvin, Iran Qazvin Qazvin Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
